With this new approval, patients now have a more convenient, needle-free option that may make it easier to start or stick with treatment
10.2307/1467828 57 LuoY.GuoW.NgoH
Common incretin-related effects discussed in the broader GLP-1 and metabolic drug class may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, or abdominal discomfort, but trial observations do not establish safe personal use of a research peptide
However, symptoms such as nausea, reflux, bloating, burping, abdominal discomfort or diarrhoea may disturb sleep, especially if they happen after eating late or lying down soon after a meal
Toss with a teriyaki glaze
Although early combination therapy may increase initial costs, it has the potential to reduce long-term healthcare expenditures by lowering the need for interventions and hospitalizations [127,128]